Kala Pharmaceuticals (KALA) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/4/2026
- Dow, S&P 500 close at record on AI-linked earnings, Mideast deal hopes
- Caterpillar stock jumps on strong earnings and revenue beat
- Optical component stocks rally on proposed U.S. ban on Chinese tech
- BofA says this memory stock could double. Here are 5 reasons why
- Merck shares rise on big Q2 earnings beat, adjusted FY outlook
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Opendoor posts Q2 revenue rise as net loss widens year over year
- Palantir posts 93% revenue growth in Q2 2026, raises full-year outlook
- Grainger CFO resigns, interim replacement named
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
Kala Pharmaceuticals Reports Second Quarter 2019 Financial Results
August 6, 2019 7:00 AM EDTConference Call and Webcast Today at 8:00 a.m. ET
WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (Kala) (NASDAQ: KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY mucus-penetrating particle (MPP) Drug Delivery Technology, today reported financial results for the second quarter ended June 30, 2019.
We are very pleased with our results in the second quarter. The INVELTYS launch is progressing well, with positive feedback from physicians and strong growth in prescriptions, market share, and revenues compared to the first quarter, said Mark Iwicki, Chairman,... More
